1. Home
  2. ASMB vs SCLX Comparison

ASMB vs SCLX Comparison

Compare ASMB & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • SCLX
  • Stock Information
  • Founded
  • ASMB 2005
  • SCLX 2011
  • Country
  • ASMB United States
  • SCLX United States
  • Employees
  • ASMB N/A
  • SCLX N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ASMB Health Care
  • SCLX Health Care
  • Exchange
  • ASMB Nasdaq
  • SCLX Nasdaq
  • Market Cap
  • ASMB 100.5M
  • SCLX 81.7M
  • IPO Year
  • ASMB 2010
  • SCLX N/A
  • Fundamental
  • Price
  • ASMB $14.72
  • SCLX $0.55
  • Analyst Decision
  • ASMB Buy
  • SCLX Strong Buy
  • Analyst Count
  • ASMB 2
  • SCLX 3
  • Target Price
  • ASMB $35.00
  • SCLX $11.33
  • AVG Volume (30 Days)
  • ASMB 23.4K
  • SCLX 184.3K
  • Earning Date
  • ASMB 11-07-2024
  • SCLX 12-03-2024
  • Dividend Yield
  • ASMB N/A
  • SCLX N/A
  • EPS Growth
  • ASMB N/A
  • SCLX N/A
  • EPS
  • ASMB N/A
  • SCLX N/A
  • Revenue
  • ASMB $28,326,000.00
  • SCLX $50,833,000.00
  • Revenue This Year
  • ASMB $267.67
  • SCLX $32.77
  • Revenue Next Year
  • ASMB $46.15
  • SCLX $50.71
  • P/E Ratio
  • ASMB N/A
  • SCLX N/A
  • Revenue Growth
  • ASMB N/A
  • SCLX 9.41
  • 52 Week Low
  • ASMB $8.16
  • SCLX $0.54
  • 52 Week High
  • ASMB $19.93
  • SCLX $2.63
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 35.66
  • SCLX 28.28
  • Support Level
  • ASMB $15.92
  • SCLX $0.54
  • Resistance Level
  • ASMB $17.48
  • SCLX $0.74
  • Average True Range (ATR)
  • ASMB 1.07
  • SCLX 0.11
  • MACD
  • ASMB -0.25
  • SCLX -0.03
  • Stochastic Oscillator
  • ASMB 28.54
  • SCLX 2.24

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: